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L ung transplantation has become an establishedoption in the therapy of end-stage lung disease.1 The
major disease subgroups for which lung transplantation
is considered are emphysema, suppurative lung disease,
pulmonary hypertension, and pulmonary fibrosis.2
Overall survival is improving, but figures remain inferi-
or to the results achieved with transplantation of other
organs.3 However, even for patients in whom lung trans-
plantation may not provide a survival benefit, quality of
life and pulmonary function indices are improved.1
Suppurative lung diseases pose several problems to
Objective: The purpose of this study was to compare outcomes after
heart-lung or double-lung transplantation in patients undergoing trans-
plantation because of end-stage suppurative lung disease. Methods: We
reviewed our experience in patients with cystic fibrosis or bronchiecta-
sis who had heart-lung or double-lung transplantation between January
1988 and September 1997. Twenty-three patients (14 male, 21 cystic
fibrosis) had heart-lung transplantation and 24 patients (8 male, 19
cystic fibrosis) had double-lung transplantation. There were no statisti-
cally significant differences between the groups in age, weight, preoper-
ative creatinine level, cytomegalovirus status, maintenance immuno-
suppression, or donor demographics. Patients received induction
therapy with monoclonal (OKT3) or polyclonal (rabbit anti-thymocyte
globulin) antibody. Results: Sixteen of 24 patients had double-lung trans-
plantation after 1994 whereas 13 of 22 patients had heart-lung trans-
plantation before 1991, allowing longer follow-up for the heart-lung
group. Mean waiting times for transplantation were 270 ± 245 days
(heart-lung) and 361 ± 229 days (double-lung; P = .20). The 1-, 3-, and
5-year actuarial survival figures were respectively 86%, 82%, and 65%
(heart-lung) and 96%, 75%, and unavailable (double-lung; P = no sig-
nificant difference). The 1-, 3-, and 5-year rates of freedom from oblit-
erative bronchiolitis were respectively 77%, 61%, and 45% (heart-lung)
and 86%, 78%, and unavailable (double-lung; P = no significant differ-
ence). Linearized overall infection rates (events/100 patient-days) were
2.05 ± 0.33 (heart-lung) and 2.34 ± 0.34 (double-lung; P = NS) at 3
months. Thirty-day survival was 100% (heart-lung) and 96% (double-
lung). There were 7 late deaths among heart-lung recipients (3 oblitera-
tive bronchiolitis, 2 infection, 0 graft coronary artery disease, 2 other)
whereas 2 late deaths related to obliterative bronchiolitis occurred in
double-lung recipients. Graft coronary artery disease (all stenoses <
50%) affected 15% of heart-lung survivors, whereas 3 double-lung
recipients (12.5%) required either bronchial dilatation or stenting.
Conclusion: Heart-lung and double-lung transplantation provide similar
palliation for patients with end-stage suppurative lung disease.
Therefore double-lung transplantation should be the preferred opera-
tion for most patients with end-stage suppurative lung disease. (J
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the transplant team. Transplantation options are limit-
ed, with single-lung transplantation having no practical
role because bilateral sepsis mandates excision of both
lungs.2 In addition, patients frequently have extensive
pleural adhesions that prolong the operative time, are
associated with an increased risk of bleeding, and
potentially increase the postoperative recovery time.
Finally, patients with cystic fibrosis (CF) make up the
largest single group of patients referred for transplanta-
tion with end-stage suppurative lung disease. These
patients have nutritional deficiencies that are com-
pounded by malabsorption syndrome, colonization of
sinuses and airways with resistant organisms, and sys-
temic comorbidities including hepatic and pancreatic
dysfunction. Despite these issues, several centers have
reported survival and pulmonary function benefits after
both heart-lung4-6 and sequential double-lung7-9 trans-
plantation in patients with suppurative lung disease.
The purpose of this review is to compare outcomes
after heart-lung and double-lung transplantation in
patients with suppurative lung disease at Stanford
University Medical Center.
Methods
The study consisted of a retrospective review and analysis
of the cases of patients who had undergone either heart-lung
or double-lung transplantation because of end-stage suppura-
tive lung disease at Stanford. All patients with CF or
bronchiectasis who underwent transplantation between
January 1988 and September 1997 were included. Patient
information for this study was obtained from the Stanford
Transplant Database and a thorough review of clinical records.
Patient selection. Patients with end-stage suppurative lung
disease who were accepted for transplantation generally had
a forced expiratory volume in 1 second (FEV1) less than 30%
of predicted, a PO2 less than 60 mm Hg, and a PCO2 greater
than 45 mm Hg while breathing room air. Selection criteria
were similar to those published elsewhere.10 Acutely ill
patients, including those requiring mechanical ventilation,
were not considered good candidates and no patient who was
receiving ventilator support underwent transplantation during
the period of this study.11 Potential recipients were motivated
and had a suitable social support network. Transplantation
was not offered to patients with significant multisystem dis-
eases or those with a recent history of malignancy. Patients
with CF with extrapulmonary sites of infection, those with
pan-resistant Pseudomonas, Burkholderia cepacia, or
Aspergillus, were temporarily taken off of the active list until
the infection was cleared. Patients with CF underwent sinus
flushing via maxillary antrostomies before being listed. The
same criteria were applied in selecting patients for both heart-
lung and double-lung procedures.
Psychological support and exercise rehabilitation of the
patients were maximized once the patient was accepted for
transplantation. Nutritional supplementation was optimized,
with percutaneous gastrostomy if necessary, and regular pro-
phylactic sinus flushing was continued to decrease the bacte-
rial load in the upper respiratory tract in the patients with CF.
Operative techniques. Patients received heart-lung trans-
plantation, in combination with “domino-donor” cardiac
transplantation when possible,4,12 or sequential double-lung
transplantation. Domino-donor hearts were treated the same
as any donor heart and were placed in the normal distribution
algorithm for allocation based on the waiting time of candi-
dates on the United Network for Organ Sharing (UNOS) car-
diac transplant list. Ten recipients of heart-lung allografts
donated their native heart for cardiac transplantation. There
were various reasons for not using the other 13 native hearts
for cardiac transplantation: no suitable recipient was identi-
fied because of size and/or blood type (n = 9), poor left ven-
tricular function (n = 3), and transplantation occurred before
implementation of the domino procedure (n = l).
Patients were not prospectively matched with donors
according to cytomegalovirus status. In heart-lung recipients
we ensured that the donor weight was within 25% of the
recipient weight. Heart-lung transplantation was initially the
preferred procedure for patients with suppurative lung dis-
ease on the basis of our experience with this operation for
patients with pulmonary hypertension and congenital heart
disease.13 The trend gradually evolved to favor sequential
double-lung transplantation as other centers reported their
experiences with that procedure.7-9
The technique of organ procurement has been described
previously.14 Alprostadil (prostaglandin E1) was infused 15
minutes before procurement. Pulmonoplegic solution, con-
sisting of modified Euro-Collins solution with 8 mEq/L
MgSO4 and 65 mL/L of 50% dextrose, was infused into the
pulmonary artery just before aortic crossclamping. If the
recipient was to receive a double-lung transplant, the pul-
monary artery was divided at its bifurcation and the trachea
was divided at the carina. The lungs were separated just
before implantation during the recipient operation. In 10
heart-lung cases the heart was preserved for domino-donor
operation. Dissection of the superior vena cava was extended
cranially in both the donor and heart-lung recipient. Direct
bicaval anastomoses were performed in the domino trans-
plantation procedure, and this technique has been adapted to
all heart-lung procedures.
Heart-lung transplantation was done via a median sternoto-
my early in the series and via a transverse thoracostomy
(“clamshell”) incision later.15 Great care was taken to preserve
phrenic nerve pedicles and to avoid damage to the vagus
nerves. The posterior pericardium was left intact and
bronchial collateral vessels were diligently controlled to avoid
hemorrhage from the posterior mediastinum. During excision
of the septic lungs, shed blood was discarded to avoid bacter-
ial contamination. The tracheal anastomosis was sutured end
to end with running 3-0 polypropylene sutures. We did not
“telescope” or wrap the anastomosis with omentum.
Double-lung transplantation was done through a clamshell
incision to maximize exposure of the pleural spaces. We did
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not perform the classic en bloc procedure, but preferred the
sequential double-lung technique.16 The right lung was trans-
planted first while ventilation was maintained to the left lung.
Cardiopulmonary bypass (CPB) was occasionally necessary
during implantation of the first lung. The bronchial anasto-
mosis was sutured end to end with running 4-0 polypropylene
sutures, also without telescoping or omental wrapping. We
initially attempted to avoid CPB during insertion of both
lungs, although we now believe that this is not necessary. In
most cases, once the right lung was transplanted, CPB was
instituted during implantation of the left lung. This strategy
facilitated exposure of the left hilum and gradual reperfusion
of the right lung at low pressure in an attempt to minimize
reperfusion injury.
In patients with CF, regardless of whether they had heart-
lung or double-lung transplantation, either tranexamic acid or
aprotinin was used in an attempt to reduce postoperative
hemorrhage. The argon beam coagulator was frequently used
to control hemorrhage from the pleural surface.
Postoperative care. Monitoring and nursing routines were
similar for all patients. Patients received active diuresis and
fluid infusions were minimized in the early postoperative
period, which frequently necessitated the use of vasopressor
support. Patients were extubated when oxygenation was
acceptable, hemodynamics were stable, and bleeding had
minimized and when they were awake. Patients with CF were
treated perioperatively with anti-Pseudomonas antibiotics as
guided by the most recent sputum and sinus cultures.
Prophylactic ganciclovir and cytomegalovirus immune glob-
ulin (CytoGam) were given when either the donor or recipi-
ent was cytomegalovirus seropositive.17
Triple-drug maintenance immunosuppression was used
during the study period. Cyclosporine (INN: ciclosporin)
administration was begun 12 to 24 hours after transplantation
once hemodynamics and urine output were stable. The target
level was 150 to 200 ng/dL by postoperative day 7.
Azathioprine was given at 2 mg/kg per day after initial load-
ing with 4 mg/kg in the operating room. Maintenance
dosages were guided by the white blood cell count.
Methylprednisone was given at a dose of 500 mg in the oper-
ating room after protamine administration and then 125 mg
every 8 hours for the first 24 hours. Steroids were then with-
held for 2 weeks to allow bronchial healing, after which oral
prednisone administration was started at a dosage of 0.6
mg/kg in 2 divided doses. Steroids were weaned over a peri-
od of 3 to 4 weeks to a maintenance dosage of 0.2 mg/kg per
day. Perioperative induction therapy was routinely used dur-
ing the study period. Patients received either OKT3 (5
mg/day) or rabbit anti-thymocyte globulin (RATG; 2.5 mg/kg
per day), on the basis of the availability of locally produced
RATG. We observed fewer episodes of rejection and
improved survival in patients treated with RATG and, as a
consequence, the majority of patients in this study received
RATG.18 Once patients were ambulatory and tolerating a nor-
mal diet, they were discharged from the hospital.
Follow-up. Patients were followed up by the Heart-
Lung/Lung Transplant Service. They were seen twice a week
for the first 3 weeks and then weekly for another 4 weeks.
Consultations were then spaced according to progress.
Patients remained at the Stanford Home-tel to receive ambu-
latory treatment for the first 3 months, after which consulta-
tions were spaced according to progress. Long-term follow-
up consultations were undertaken at least once a year, but
usually about once every 6 months. Surveillance broncho-
scopic examination was undertaken at 2, 4, 8, and 12 weeks
and then at 6 months and 1 year. Pulmonary function tests, a
chest radiograph, and arterial blood gas evaluations were
done at each clinic visit. Patients with CF were followed up
by the otolaryngology service and received frequent sinus
flushes.
Statistical analysis. Numeric results are expressed as
mean ± SD. Differences in age, height, weight, and operative
times (continuous variables) were analyzed by the 2-tailed t
test. Differences in sex, proportion of patients with CF, and
cytomegalovirus status (discrete variables) were compared by
continuity-adjusted χ2 test. Actuarial life-table data were cal-
culated by the Cutler-Ederer method. Time-related event-free
rates are reported from actuarial estimates as the mean ± SE.
Comparison between actuarial curves was made by the
Gehan method. The linearized rate of events was calculated
as the number of events occurring per 100 patient-days. We
acknowledge the severe limitations of this very small retro-
spective study.
Results
Between January 1988 and September 1997, 47
patients underwent transplantation because of suppura-
tive lung disease. Twenty-three patients had heart-lung
transplants and 24 patients had double-lung trans-
plants. Pretransplantation patient demographics are
shown in Table I. The groups were generally compara-
ble in terms of age, sex, preoperative diagnosis, height,
weight, creatinine level, bilirubin level, cytomegalo-
virus status, and donor characteristics. All patients
received induction therapy. Fourteen of 23 in the heart-
lung group received RATG, as did 21 of 24 in the dou-
ble-lung transplantation group. All the other patients
received OKT3. The annual numbers and types of pro-
cedures are listed in Table II. Thirteen of 23 patients
had heart-lung transplantation before 1991, whereas 16
of 24 patients had double-lung transplantation after
1994. The domino-donor operation was begun in 1989
and 10 of the hearts of heart-lung recipients were
donated for cardiac transplantation.
Perioperative data for the two groups are shown in
Table III. Mean waiting time for heart-lung transplan-
tation was 270 ± 245 days and for double-lung trans-
plantation was 361 ± 229 days (P = .20, not signifi-
cant). Fifteen of 24 patients receiving double-lung
transplantation had CPB for insertion of the second
lung, 1 patient required CPB support for insertion of
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both lungs, and 8 patients had double-lung transplanta-
tion done without the use of CPB. There were no sta-
tistically significant differences in outcomes between
patients who required CPB and patients who had the
operation without CPB. Ischemic times for insertion of
the heart-lung block were not significantly shorter than
ischemic times for insertion of the first lung (P = .09),
but they were significantly shorter than times for the
second lung (P < .001, Table III). One patient in the
heart-lung group and 2 in the double-lung group under-
went re-exploration to control bleeding. Data were not
available for total blood use, but decreased blood loss
has been noted in all patients undergoing lung trans-
plantation, especially those with CF, since the intro-
duction of antifibrinolytic agents. The duration of ven-
tilation and intensive care unit days required by each
group were similar. Total length of hospital stay tended
to be longer in heart-lung recipients, although this did
not reach statistical significance. No patient underwent
retransplantation because of early graft failure. Thirty-
day survival for the heart-lung transplant group was
100%. There was 1 early death in the group undergoing
double-lung transplantation. This patient was a 46-
year-old man with CF. He had recently required venti-
lator support for a period of 10 days and was severely
physically and nutritionally weakened. He had exten-
sive adhesions and therefore had a prolonged insertion
time for both lungs (276 and 359 minutes). Both lungs
were transplanted during CPB because of inadequate
ventilation. After the operation the patient had exten-
sive blood loss necessitating transfusion and re-explo-
ration because of bleeding. Acute respiratory distress
syndrome subsequently developed, and the patient
required extracorporeal membrane oxygenation. He
Table I. Demographics of heart-lung recipients, double-lung recipients, and donors
Heart-lung Heart-lung Double-lung Double-lung Comparison 
Variable recipients donors recipients donors (recipients)
Patient No. 23 23 24 24
Age (y) 29 ± 8.9 27 ± 13.7 30 ± 10.1 28 ± 13.8 P = .88 (NS)
Weight (kg) 49 ± 13.3 58 ± 16.9 49 ± 9.0 59 ± 12.9 P = .95 (NS)
Height (cm) 163 ± 17.3 167 ± 16.7 157 ± 23.2 162 ± 10.4 P = .36 (NS)
Sex (M/F) 14/9 15/8 8/16 11/13 NS
Sex mismatch (yes/no) 5/18 9/15 NS
Domino donor (yes/no) 10/13 NA
CF/bronchiectasis 21/2 19/5 NS
CMV (positive/negative) 8/15 12/12 NS
CMV mismatch (yes/no) 8/15 7/17 NS
Data are means ± SD. Differences in age, weight, and height analyzed by 2-tailed t test; differences in sex, diagnosis, and cytomegalovirus (CMV) status analyzed
by the Pearson χ2 test. CF, Cystic fibrosis; NS, not significant; NA, not applicable.
Table II. Transplants undertaken for suppurative lung
disease
Heart-lung Double-lung 
Year transplants transplants
1988 3 0
1989 4 0
1990 6 1
1991 2 1
1992 1 1
1993 0 2
1994 3 3
1995 2 3
1996 1 4
1997 1 9
Total 23 24
Table III. Perioperative data
Heart-lung Double-lung 
Variable recipients recipients Comparison
Waiting time (d) 270 ± 245 361 ± 229 P = .20 (NS)
Ischemic time (min)
Heart-lung 190 ± 92
First lung 232 ± 70 P = .09* (NS)
Second lung 331 ± 87 P < .001*
CPB (yes/no) 23/0 15/9
CPB time (min) 168 ± 37 166 ± 68 P = .94 (NS)
Reoperation for bleeding 1 2
Duration of ventilation (d)
Mean 6.4 ± 10.9 9.4 ± 29.7 P = .65 (NS)
Median 1 1
Range 1-38 1-144
Hospital stay (d)
Mean 38 ± 34 26 ± 25 P = .18 (NS)
Median 27 18
Range 13-161 2-133
Data are means ± SD. Differences are analyzed by 2-tailed t test. NS, Not
significant.
*Versus heart-lung.
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continued to bleed, his condition became hemodynam-
ically unstable, and sepsis developed. Despite maximal
inotropic and pressor support, the patient died on the
second postoperative day.
Actuarial survival was similar for the two groups (Fig
1). Longer follow-up data were available for heart-lung
recipients because of more frequent use of this proce-
dure early in the series. Survivorship at 1, 3, and 5
years, respectively, was 86%, 82%, and 65% for heart-
lung recipients and 96%, 75%, and unavailable for dou-
ble-lung recipients. There was no statistically signifi-
cant difference between survival figures by Gehan
analysis. Actuarial survivorship for patients who
received induction therapy with RATG at 1, 3, and 5
years, respectively, was 84%, 75%, and 56% for heart-
lung recipients (n = 13) and 95%, 84%, and unavailable
for double-lung recipients (n = 21). There was no sta-
tistically significant difference in survival between the
transplantation procedure groups when subjects who
received OKT3 induction therapy were excluded.
Linearized rates of bacterial, fungal, protozoal, viral,
and overall infections for the two groups are shown in
Table IV. There was no significant difference for any
type of infection at any period. There were 2 deaths as
a result of infection after heart-lung transplantation
that occurred after 3 and 4 months, respectively. Both
patients had complicated postoperative courses, were
never discharged from the hospital, and had multior-
gan failure before dying of sepsis. There were no long-
term infection-related deaths in double-lung
recipients.
Actuarial rates of freedom from biopsy-proven oblit-
erative bronchiolitis (OB) are shown in Fig 2. There
was no significant difference between the two groups.
Actuarial rates of freedom from lung rejection at 3
months and at 1, 3, and 5 years, respectively, in heart-
lung recipients were 43%, 37%, 21%, and 21% and in
double-lung recipients were 61%, 56%, 48%, and
unavailable (P = .10, Fig 3). Actuarial rates of freedom
from heart rejection at 3 months and 1, 3, and 5 years,
Fig 1. Comparison of actuarial survival between heart-lung
and double-lung recipients. Time-related event-free rates are
mean ± SE. There was no difference between the curves by
Gehan testing.
Fig 2. Comparison of actuarial freedom from biopsy-proven
OB between heart-lung and double-lung recipients. Time-
related event-free rates are mean ± SE. There was no differ-
ence between the curves by Gehan testing.
Table IV. Linearized infection rates (events/100 patient-days)
Time period (mo)
0-3 3-6 6-12 12-24
Type of infection H-L D-L H-L D-L H-L D-L H-L D-L Comparison
Bacterial 1.03 (0.23) 1.55 (0.28) 0.11 (0.08) 0.45 (0.15) 0.14 (0.09) 0.20 (0.11) 0.17 (0.10) 0.22 (0.14) NS
Viral (CMV) 0.61 (0.18) 0.50 (0.16) 0.17 (0.10) 0.50 (0.16) 0.06 (0.06) 0.10 (0.08) 0.06 (0.11) 0.11 (0.07) NS
Fungal 0.34 (0.13) 0.29 (0.12) 0.11 (0.07) 0 (0) 0 (0) 0.02 (0.02) 0.02 (0.02) 0.06 (0.05) NS
Overall 2.05 (0.33) 2.34 (0.34) 0.44 (0.16) 0.95 (0.22) 0.21 (0.11) 0.33 (0.14) 0.26 (0.12) 0.38 (0.17) NS
Data are means (SD). H-L, Heart-lung transplant; D-L, double-lung transplant; NS, not significant; CMV, cytomegalovirus.
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respectively, in heart-lung recipients were 80%, 75%,
69%, and 61% (Fig 4). Actuarial rates of freedom from
angiographically significant graft coronary artery dis-
ease (all stenoses were <50%) at 1, 3, and 5 years were
100%, 85%, and 85%, respectively. No patient died of
cardiac complications or received cardiac retransplan-
tation in the heart-lung cohort. However, in one heart-
lung recipient superior vena caval obstruction devel-
oped, which was treated with radiologically guided
stent placement. A second patient, an 8-year heart-lung
transplant survivor, has mitral regurgitation from myx-
omatous degeneration of the donor mitral valve. He is
currently being considered for mitral valve replace-
ment.
A list of surgical and medical complications is shown
in Table V. Three patients in the double-lung group had
significant bronchial stenoses. Two of these instances
resolved with balloon dilatation. A third patient, who
also had a course severely complicated by B cepacia
pneumonia, required 3 stents to the left lung and 3 to
the right lung. This patient remains in New York Heart
Association class IV and is currently relisted for heart-
lung transplantation. A degree of gastric atony was
encountered in most patients in both groups because of
the proximity of the surgical dissection to the vagus
nerves. This was managed with cisapride or metaclo-
pramide and only 1 patient in each group had severe
symptoms persisting longer than 1 week. One double-
lung recipient had a significant gastrointestinal tract
bleeding episode. This resolved with transfusion and
medical management. One double-lung recipient with
CF had cholecystitis necessitating cholecystectomy 5
Fig 3. Comparison of actuarial freedom from lung rejection
between heart-lung and double-lung recipients. Time-related
event-free rates are mean ± SE. The difference between the
curves did not reach statistical significance by Gehan testing
(P = .10).
Fig 4. Actuarial freedom from heart rejection for heart-lung
recipients. Time-related event-free rates are mean ± SE.
Table V. Complications
Heart-lung Double-lung 
Complication transplants transplants
Surgical
Airway
Stricture 0 3
Stent 1
Balloon 2
Dehiscence 0 0
Gastrointestinal
Gastric atony (>1 wk) 1 1
Cholelithiasis 0 1
Bleeding 0 1
Pulmonary
Resection 0 1
Miscellaneous
Axillary vein thrombosis 0 1
SVC anastomotic stricture 1 NA
Graft failure (re-listed) 0 1
Medical
Cardiac
Graft coronary disease (<50%) 3 NA
Graft mitral valve prolapse 1 NA
Renal
Temporary dialysis 1 2
Nephrotic syndrome 2 0
Central nervous system
Cerebrovascular accident 0 1
Seizure 1 2
Metabolic
New insulin-dependent diabetes 1 1
SVC, Superior vena cava; NA, not applicable.
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months after transplantation. In 1 patient in the double-
lung group an axillary vein thrombosis developed. One
patient in the heart-lung group had the development of
renal failure necessitating temporary dialysis, as did 2
in the double-lung group. One patient in the heart-lung
group and 2 in the double-lung group had temporary
seizure disorders.
There were 7 late deaths in the heart-lung transplant
group, 2 of which were a result of infectious complica-
tions as previously described. A third patient died 38
days after transplantation of complications after a cere-
brovascular accident. A fourth patient died after 3 years
of liver failure, which was complicated by severe OB.
The remaining 3 deaths were caused by OB-related
complications after 1, 3, and 4 years, respectively.
There were 2 late deaths in the double-lung recipients,
both of which occurred after almost 2 years and were
related to OB.
Patient pulmonary function test results are shown in
Fig. 5, A, for forced vital capacity and Fig. 5, B, for
FEV1. These demonstrate an immediate and sustained
improvement in forced vital capacity and FEV1 after
both heart-lung and double-lung transplantation.
Discussion
Survival and long-term pulmonary function benefits
were achieved in patients with suppurative lung disease
after both heart-lung and double-lung transplantation
with no apparent survival advantage being observed for
either procedure. Each procedure has both theoretical
and practical advantages. Our strategy in the late 1980s
and early 1990s was to perform heart-lung transplanta-
tion in patients with suppurative lung disease because
of our early experience and familiarity with this proce-
dure.13 We gradually evolved our approach as other
centers reported good results with double-lung trans-
plantation.7-9 On the basis of the present analysis, dou-
ble-lung transplantation is the preferred operation for
patients with end-stage suppurative lung diseases.
Although the first lung transplantation was done by
Hardy in 1963, it was not until the initial experience
with heart-lung transplantation at Stanford that a rea-
sonable degree of success was achieved with pul-
monary replacement.2,13 Shortly afterward, improved
results of single-lung transplantation were reported in
subjects with pulmonary fibrosis.19 Because bilateral
sepsis mandates the excision of both lungs in suppura-
tive lung disease, the first procedure done in these
patients was heart-lung transplantation. The first dou-
ble-lung transplantations for CF were done by the en
bloc technique. There were initial concerns that tra-
cheal anastomotic healing would be poorer than after
heart-lung transplantation, because of the loss of medi-
astinal collaterals. The technique of double-lung trans-
plantation evolved to a bibronchial anastomosis with
the use of CPB support.20 Later, the clamshell incision
A B
Fig 5. Early and sustained improvement in pulmonary function test results after heart-lung and double-lung trans-
plantation (Tx): A, forced vital capacity (FVC); B, FEV1. Columns show mean with SE. The n value is shown in
parentheses.
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was introduced, which allowed improved exposure and
introduction of the sequential insertion technique, with
or without CPB.21 Some centers attempt to avoid CPB
to minimize blood loss and the subsequent need for
blood transfusion and possible reperfusion injury.8
Others prefer to use CPB during insertion of the second
lung to reduce operative time, improve exposure, and
avoid overperfusing the newly implanted first lung.7
Fears that patients with CF would do worse than
other patients after transplantation have not been real-
ized. Indeed, an analysis of recent data from the Joint
United Network for Organ Sharing (UNOS) and the
International Society of Heart and Lung Trans-
plantation (ISHLT) indicated that among all patients
referred for lung transplantation, the clearest survival
benefit is in patients with CF.1 This is largely because
survival of patients with CF awaiting transplantation is
significantly worse than that of patients with other dis-
eases such as emphysema. As a result, the requirement
for organs for lung transplantation in suppurative lung
disease is greater than the current limited supply.
The successful introduction of sequential double-
lung transplantation for CF led several investigators to
question whether heart-lung transplantation should
remain an option for these patients.2,7,8 There are sev-
eral theoretical advantages of double-lung transplanta-
tion. The incidence of accelerated graft coronary artery
disease after heart-lung transplantation may be as high
as 12%,22 and this is avoided in double-lung transplan-
tation, as is the concern of placing a denervated heart in
a patient without cor pulmonale. Improved anastomot-
ic techniques have reduced the incidence of airway
anastomotic dehiscence and strictures in double-lung
transplantation.7,8,20,21 There may be less mediastinal
bleeding in double-lung transplantation, especially if
CPB can be avoided, whereas reoperation rates because
of bleeding as high as 28% have been reported in heart-
lung transplantation.23 The vagus nerves may be at less
risk in double-lung transplantation.7 Finally, initial
reports of outcome after heart-lung transplantation in
patients with CF in the United States were disappoint-
ing, with 1-year survival of only 42%.24
Conversely, some transplantation centers continue to
maintain that heart-lung transplantation retains certain
advantages for patients with end-stage suppurative lung
diseases.5 Early reports of heart-lung transplantation in
patients with CF in the United Kingdom showed a
promising 1-year survival of about 75%.4,5 There is
only one airway anastomosis and this has a lower risk
of dehiscence because it retains its blood supply
through coronary-to-bronchial collateral vessels.6 The
tracheal airway is larger, which reduces the risk of
stricture encountered after bronchial anastomoses,6 and
more “infected” airway is removed. The occasionally
high incidence of airway complications, reported by
some centers in double-lung transplantation,9,25 is
therefore avoided. The operation is simpler and there-
fore faster with shorter ischemic times than those
reported in some series of double-lung transplantation.
Although anecdotal reports have found that a pro-
longed ischemic time does not necessarily correlate
with poor postoperative pulmonary function,8 basic
principles motivate the transplantation surgeon to keep
organ ischemic time as short as possible. The potential
use of domino-donor hearts means that organs should
not be wasted. The domino-donor heart has the poten-
tial advantages of a conditioned right ventricle, of
being fully analyzed before transplantation, and of not
being from a brain-dead donor. Finally, the current
UNOS policy is to give priority to patients on the heart-
lung waiting lists, which may result in shorter waiting
times for these recipients. In the present study we
sought to assess whether the theoretical advantages of
the 2 procedures translated into actual survival or clin-
ical benefits for patients with end-stage suppurative
lung disease.
Organs were offered by our organ procurement orga-
nization for individual patients in order of longest wait-
ing time. According to guidelines agreed to by UNOS,
priority was given to heart-lung candidates before dou-
ble-lung candidates. Length of waiting time was short-
er for heart-lung recipients in this study, although this
figure did not reach statistical significance. Waiting
times tend to be longer now than they were several
years ago when most of the heart-lung patients in this
study received their transplants, but waiting-list priori-
ty still favors this group.
We found no difference in the incidence of re-explo-
ration because of bleeding between the two groups in
this study. Data on blood transfusion requirements
were not available. Postoperative emphasis on mini-
mizing transfusions and using pressors when necessary
has helped reduce length of ventilation and intensive
care unit stay in recent years. There was no significant
difference between the groups in duration of ventilation
and hospital stay. The tendency, although not signifi-
cant, for double-lung recipients to have shorter hospital
stays might reflect the emphasis on early discharge in
recent years when most double-lung transplantation
procedures were done.
The major end point of our study was patient sur-
vival. There was no difference between the two groups,
both early and at longer-term follow-up. The survivor-
ship is actually higher than that for patients undergoing
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these two procedures at Stanford for other diagnostic
indications. Overall rates of lung rejection and OB
were also similar in the two groups. Accelerated graft
coronary artery disease, which affects 15% of heart-
lung survivors in this study, has not resulted in death or
retransplantation. We suspect that OB affects patients
more aggressively than graft coronary artery disease
and is the major chronic rejection equivalent after
heart-lung transplantation.26 This incidence of OB is
similar to that described in other studies of double-
lung8 and heart-lung6 transplantation. The double-lung
group had a higher incidence of airway complications,
although our results compared well with those of some
reported series.9,25 It is possible that earlier administra-
tion of steroids, which we avoid until 2 weeks after
transplantation to assist bronchial healing, could actu-
ally help reduce airway complications by decreasing
the immunologic effects of ischemia and early rejec-
tion.5 The patient groups had similar lung function
improvements at both early and longer-term follow-up.
Rates of cytomegalovirus infection were similar for
both groups. Our policy of ganciclovir and cyto-
megalovirus immune globulin (CytoGam) prophylaxis
has been instituted since 1990 and affected almost all
the patients in both groups in this study.17 Aerosolized
amphotericin B prophylaxis was instituted at Stanford
in 1993 and would have affected almost all double-lung
transplant recipients and a minority in the heart-lung
transplant group.27 Despite this, there was no signifi-
cant difference in the rate of fungal infection between
the two groups.
In keeping with procedures at most centers in the
United States, candidates referred for transplantation
because of end-stage suppurative lung disease at
Stanford during the past few years have been listed for
double-lung transplantation. However, the present
analysis suggests that neither double-lung nor heart-
lung transplantation has any advantage from a survival
or pulmonary function perspective. Indeed, both pro-
cedures have certain advantages and drawbacks. We
continue to list most of our patients for double-lung
transplantation alone. Patients with CF who require
simultaneous liver transplantation are listed for heart-
lung transplantation because of the shorter operative
time required to perform the thoracic procedure. We
double-list patients at the extremes of height and
weight, as well as more critically ill patients, so that
they obtain maximum benefit on the UNOS waiting
list.
New medical treatments and refinements in gene
therapy might, in the future, improve survival and qual-
ity of life in patients with CF.28,29 At present, however,
because both heart-lung and double-lung transplanta-
tion provide similar palliation for patients with end-
stage suppurative lung disease, double-lung transplan-
tation is the preferred operation for this group of
patients primarily because the recipient retains his or
her own normally functioning heart.
We thank Tom McCloskey for help with preparing the
manuscript. We also thank Pat Gamberg and Joan Miller for
assistance with data acquisition.
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Discussion
Dr Thomas M. Egan (Chapel Hill, NC). Dr Barlow and
his colleagues from Stanford have had excellent results with
a challenging group of patients. Forty patients with CF were
among 47 with suppurative end-stage lung disease who
underwent either heart-lung or double-lung transplantation
with an operative survival of 94% and impressive 1-year actu-
arial survival.
We have performed double-lung transplantation in 79
patients with CF and have achieved a 1-year actuarial survival
of 82% and a 5-year actuarial survival of 58%. Unlike your
group, we have not excluded patients with Aspergillus or B
cepacia colonization. Given your excellent results, do you
intend to liberalize your criteria to offer transplantation to
more patients with CF?
We have attempted to avoid CPB, using it in fewer than
15% of our cases. Your data suggest that in the era of apro-
tinin, the use of CPB may be quite safe and acceptable for this
operation.
I think the major issue here, though, is the appropriate dis-
tribution of scarce donor organs for a variety of patients with
end-stage thoracic diseases. In 1996, 805 lung transplanta-
tions were done, compared with only 39 heart-lung transplan-
tations in the United States. Whereas deaths on both the lung
and heart-lung lists continue to grow, there were more deaths
on the list than transplantations for intended heart-lung recip-
ients. In short, patients who need heart-lung transplantation
are at a substantial disadvantage across the United States and
are more likely to die waiting than to receive organs.
The authors allude in their manuscript to a peculiar local
situation that has afforded them a relatively short waiting
time for heart-lung recipients. I believe this is one of the acci-
dents of geography that the new proposed rule for organ dis-
tribution by the Department of Health and Human Services is
intended to address.
Subjecting patients with normal hearts to the risk of graft
coronary disease is difficult to justify. What happens to the
domino heart? Is it put back into the organ distribution algo-
rithm for all potential recipients, or is this domino operation
a veiled attempt at what some might consider cardiac piracy
to enable a center to perform 2 transplantations when that
center might only acquire 1 organ if another distribution algo-
rithm were used?
This paper is an important contribution precisely because it
demonstrates convincingly that there is no advantage of
heart-lung transplantation over double-lung transplantation
for patients with suppurative lung disease, and it will lend
support to efforts to distribute allografts to potential heart-
lung recipients more equitably across the country.
Dr Barlow. The first of your 3 major questions concerns
liberalization of criteria for transplantation. Of interest, the
patient with graft failure who was relisted for heart-lung
transplantation had a B cepacia infection and pneumonia, and
I think that may have put a temporary brake on liberalizing
the listing of patients. The other issue, of course, is that we
have several patients on our double-lung list at all times, and
we are not looking for patients at the moment, we are look-
ing for organs, so I think we are unlikely to liberalize criteria.
With regard to performing the procedure without CPB, I
know from your own series that the bleeding times are pro-
longed as a consequence of the use of CPB. We have not done
any operations without CPB at Stanford during the period
that I have been there, but I am told by Dr Robbins and the
other surgeons with more experience with it that it is consid-
erably more difficult. Bleeding has not been a problem.
With regard to organ distribution, at Stanford the domino-
donor heart goes into the pool, and often we will have a team
from a different institution come and get the heart, so it does
not become our own. This is not the case, for interest’s sake,
in the United Kingdom.
I think in terms of assessing which patients should have
organs, the question can be answered in terms of both the
individual patient and the transplantation population. We
have 2 patients who are listed for a simultaneous liver trans-
plantation, and they are both listed for heart-lung transplanta-
tion alone because of the shorter procedure times so they can
move on to the second phase.
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With regard to others, patients at the extremes of heights
and weights we would probably list for both procedures, and
also very sick patients we would probably list this way so
they can enjoy the benefits of both lists. Presumably that is a
regional thing in California that does not apply elsewhere, but
it does apply to us.
As far as the patient group is concerned, if you are in a cen-
ter where distribution would give you the hearts, then the
domino-donor heart from a non–brain dead donor with a pre-
conditioned right ventricle would be nice to keep in your
pool. It is also good to think that some other patient in our
area is benefiting from that if it does not make any difference
to the recipient with CF whether he or she receives a heart-
lung or a double-lung block, ultimately. As concerns the
reports heard at this meeting, however, in which longer organ
ischemic times may be associated in older donors with poor-
er survival and outcome, our average ischemic time for inser-
tion of the second lung is 51⁄2 hours. I believe other series have
times closer to 7 hours, which was the cutoff reported at this
meeting at which survival actually deteriorated. If you have a
fair number of patients on your overall lists listed for heart-
lung transplantation, then you could accept organs from far-
ther away, knowing that the insertion time is going to be
shorter.
Dr G. Alexander Patterson (St Louis, Mo). With respect
to the comment you just made, it seems to me that if the
organs are coming from a really long way, the lung is more
likely to function than the heart after transplantation. If you
are talking about really long distances, you are limited more
by cardiac ischemia than by lung ischemia.
You mentioned that allocation of recipients to heart-lung or
lung transplantation is made on the basis of individual crite-
ria, and I still do not understand that clearly. You mentioned
the combined liver transplantation situation as one example.
Is it also possible that you allocate patients to bilateral
sequential lung transplantation or heart-lung transplantation
depending on the availability of the organ? In other words, if
you were offered a heart-lung block, would you just do a
heart-lung transplantation by preference or would you do a
bilateral lung transplantation by preference?
Dr Barlow. Until recently we had been listing patients for
double-lung transplantation only. Our current philosophy is
to return in effect to what the situation was about 5 years ago;
that is, some patients are listed for both procedures if they get
insurance clearance. Then we would be able to allocate a
heart-lung block, if that was offered to us, whereas if we were
only offered lungs and the heart was to go to a status I cardiac
recipient, then we would do the double-lung transplantation.
In terms of the individual patient criteria, the cases in which
you might consider listing a patient for both procedures
would be those in which you wanted that patient to enjoy the
benefits of being on the two lists.
